Ivastine

Rivastigmine, the active ingredient in Ivastine, is a cholinesterase inhibitor presented as a transdermal patch for transdermal use. It treats Alzheimer's disease and Parkinson's disease dementia in adults. GNH USA supplies Ivastine as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivastine is a cholinesterase inhibitor used to address cognitive decline in dementia-related conditions. - Alzheimer's disease: improves cognition, memory, and daily functioning in mild to moderate stages. - Parkinson's disease dementia: helps alleviate cognitive symptoms associated with Parkinsonian dementia. - Dementia associated with other neurodegenerative disorders: provides symptomatic relief of cognitive deficits.

Ivastine may cause a range of adverse reactions, most of which are related to its cholinergic activity or the transdermal delivery system.

Common Side Effects: - Nausea - Vomiting - Loss of appetite - Dizziness - Headache - Skin irritation at the patch site

Serious or Rare Side Effects: - Severe skin reactions (e.g., rash, dermatitis) - Bradycardia or syncope - Gastrointestinal bleeding or ulceration - Seizures - Anaphylactic or severe allergic reactions - Hepatotoxicity (rare).

Before initiating Ivastine therapy, clinicians should consider several safety measures. - Dose titration: start with a low‑dose patch and increase gradually as tolerated. - Cardiovascular monitoring: observe for bradycardia or syncope in patients with cardiac disease. - Gastrointestinal caution: monitor for nausea, vomiting, or ulcer risk. - Skin assessment: inspect the application site regularly for irritation or allergic reaction. - Pregnancy and lactation: use only if the potential benefit justifies the uncertain risk. - Store at room temperature: keep below 30°C, protect from moisture and direct sunlight, retain in the original pouch.

Rivastigmine can interact with several drug classes, requiring careful review of a patient’s medication list.

Major Interactions (Avoid): - Anticholinergic agents: may diminish rivastigmine efficacy. - Beta‑blockers: increased risk of bradycardia. - Other cholinesterase inhibitors: additive cholinergic effects may be unsafe.

Moderate Interactions (Monitor Closely): - Anticoagulants: potential for increased bleeding. - NSAIDs: may exacerbate gastrointestinal side effects. - CYP450 inhibitors or inducers: may alter metabolism of concomitant medications.